Literature DB >> 22679180

Circulating human hepcidin-25 concentrations display a diurnal rhythm, increase with prolonged fasting, and are reduced by growth hormone administration.

Jason S Troutt1, Mats Rudling, Lena Persson, Lars Ståhle, Bo Angelin, Anthony M Butterfield, Andrew E Schade, Guoqing Cao, Robert J Konrad.   

Abstract

BACKGROUND: Hepcidin-25 reduces iron absorption by binding to the intestinal iron transporter ferroportin and causing its degradation. Currently, little is known about the basal regulation of circulating hepcidin-25. In addition, although erythropoietin administration has been reported to decrease the circulating hepcidin concentration, information is limited regarding how other stimulators of erythropoiesis, such as growth hormone (GH), might alter hepcidin-25 concentrations.
METHODS: We used a sensitive and specific hepcidin-25 dual-monoclonal antibody sandwich immunoassay to measure hepcidin-25 in healthy human volunteers at various time points throughout the day and during 3 days of fasting and subsequent refeeding. We also measured hepcidin-25 concentrations in healthy volunteers after GH administration.
RESULTS: In healthy individuals, hepcidin-25 concentrations displayed a diurnal variation, with concentrations being lowest in the early morning and steadily increasing throughout the day before declining during the evening hours, a pattern that was not influenced by food intake. Prolonged fasting produced statistically significant increases in hepcidin-25 concentrations. Refeeding reversed this process, and GH administration markedly decreased hepcidin-25 concentrations.
CONCLUSIONS: Our results indicate that in humans, hepcidin-25 exhibits diurnal changes that can be altered by prolonged fasting, which increases hepcidin-25 concentrations approximately 3-fold after 3 days of fasting, possibly owing to a suppression of erythropoiesis that may occur during the fasting state to preserve tissue iron concentrations. In contrast, GH administration decreased hepcidin-25 concentrations by approximately 65%, presumably by stimulating erythropoiesis. These results indicate that circulating hepcidin-25 concentrations display much more dynamic and rapid variation than might have been anticipated previously.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22679180     DOI: 10.1373/clinchem.2012.186866

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  33 in total

Review 1.  Chronic Kidney Disease and Dietary Measures to Improve Outcomes.

Authors:  Oleh M Akchurin
Journal:  Pediatr Clin North Am       Date:  2019-02       Impact factor: 3.278

2.  High-dose vitamin D3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults.

Authors:  Ellen M Smith; Jessica A Alvarez; Malcolm D Kearns; Li Hao; John H Sloan; Robert J Konrad; Thomas R Ziegler; Susu M Zughaier; Vin Tangpricha
Journal:  Clin Nutr       Date:  2016-06-27       Impact factor: 7.324

3.  Pilot study of the effect of cholecalciferol supplementation on hepcidin in children with chronic kidney disease: Results of the D-fense Trial.

Authors:  Meredith A Atkinson; Stephen P Juraschek; Michael S Bertenthal; Barbara Detrick; Susan L Furth; Edgar R Miller
Journal:  Pediatr Nephrol       Date:  2016-12-24       Impact factor: 3.714

4.  High-Dose Vitamin D3 Administration Is Associated With Increases in Hemoglobin Concentrations in Mechanically Ventilated Critically Ill Adults: A Pilot Double-Blind, Randomized, Placebo-Controlled Trial.

Authors:  Ellen M Smith; Jennifer L Jones; Jenny E Han; Jessica A Alvarez; John H Sloan; Robert J Konrad; Susu M Zughaier; Greg S Martin; Thomas R Ziegler; Vin Tangpricha
Journal:  JPEN J Parenter Enteral Nutr       Date:  2017-12-11       Impact factor: 4.016

5.  Small-protein Enrichment Assay Enables the Rapid, Unbiased Analysis of Over 100 Low Abundance Factors from Human Plasma.

Authors:  Dylan J Harney; Amy T Hutchison; Zhiduan Su; Luke Hatchwell; Leonie K Heilbronn; Samantha Hocking; David E James; Mark Larance
Journal:  Mol Cell Proteomics       Date:  2019-07-15       Impact factor: 5.911

6.  Plasma hepcidin levels and anemia in old age. The Leiden 85-Plus Study.

Authors:  Wendy P J den Elzen; Anton J M de Craen; Erwin T Wiegerinck; Rudi G J Westendorp; Dorine W Swinkels; Jacobijn Gussekloo
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

Review 7.  The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients.

Authors:  Kimberly Zumbrennen-Bullough; Jodie L Babitt
Journal:  Nephrol Dial Transplant       Date:  2013-11-13       Impact factor: 5.992

Review 8.  Physiology of iron metabolism.

Authors:  Sophie Waldvogel-Abramowski; Gérard Waeber; Christoph Gassner; Andreas Buser; Beat M Frey; Bernard Favrat; Jean-Daniel Tissot
Journal:  Transfus Med Hemother       Date:  2014-05-12       Impact factor: 3.747

9.  Seven days of high carbohydrate ingestion does not attenuate post-exercise IL-6 and hepcidin levels.

Authors:  Claire E Badenhorst; Brian Dawson; Gregory R Cox; Marc Sim; Coby M Laarakkers; Dorine W Swinkels; Peter Peeling
Journal:  Eur J Appl Physiol       Date:  2016-07-05       Impact factor: 3.078

10.  Serum hepcidin in infants born after 32 to 37 wk of gestational age.

Authors:  Lieke Uijterschout; Magnus Domellöf; Staffan K Berglund; Micky Abbink; Paul Vos; Lyanne Rövekamp; Bart Boersma; Carina Lagerqvist; Cisca Hudig; Johannes B van Goudoever; Frank Brus
Journal:  Pediatr Res       Date:  2015-12-16       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.